The biotech sector has had, by its standards, a very disappointing month and company executives and investors alike will be hoping that the worst is over. Read More
With hepatitis C treatments largely figured out, biotechs and investors have turned to the newest liver disease without a treatment: nonalcoholic steatohepatitis (NASH). Read More
